Analytical Chip Technology: U.S. Markets for Lab on a Chip, DNA/Gene, Protein, and other Microarrays

3rd. Edition

Publication Date	November 2007
Publisher	Kalorama Information
Product Type	Report
Pages	276
ISBN Number	not applicable
Product Code	KAL00103

Price

£2,140.00
approximately: $3,999 | €2,714

PDF

PRINT £2,350 ($4,391 | €2,981)

Order above formats by FAX

Summary

Analytical microchips can be considered one of the fastest growing technology segments in life sciences. The range of applications to which these miniature laboratories may be directed is very broad - covering fields as different as pharmaceutical development, food testing, clinical diagnostics, forensics, and environmental analysis.

Kalorama's Analytical Chip Technology: U.S. Markets for Lab on a Chip, DNA/Gene, Protein and other Microarrasys) 3rd. Edition of its report on this exciting marketplace analyzies the world market for analytical microchips with a unique methodology -- the market is expressed in terms of its as opposed to experienced and projected revenues. As the author Ken Krul states,

The status of the current market in terms of revenues is misleading of the potential market as a whole. It does not allow for the understanding of the potential of unmet need. The difference can be as stark as the difference between the surface of the sun and the dark side of the moon.

Content

Chapter One: Executive Summary
- Current Insulin Delivery Methods
- Pulmonary Delivery
- Methodology
- Market Trends
- Summary of Findings
Chapter Two: Introduction
- The Disease
- Nature of Diabetes
- Types of Diabetes
- An Epidemic
- Related Complications
- Geriatric Issues
- New Approaches to Diabetes
- Current Insulin Delivery Techniques
- Syringes
- Pens
- Modified Insulin Delivery
- Pills
- Skin Patches
- Oral Sprays
- Inhalation Systems
- Demand and Acceptance
Chapter Three: The Market
- Overall Market for Insulin
- Market for Inhaler Systems
- Competitive Landscape
Chapter Four: Key Players And Their Technologies
- Alkermes Inc.
- Aerogen Inc.
- Aradigm Corp.
- Aventis S.A.
- Epic Therapeutics Inc.
- Generex Biotechnology
- Nektar Therapeutics
- Novo Nordisk A/S
- Pfizer Inc.
List Of Exhibits
- Exhibit 1: Prevalence of Diagnosed Diabetes by Age, US, 1980-2002
- Exhibit 2: U.S. Prevalence of Type II Diabetes Cases by Age Group 45-54 years, 55-64 years, 65-74 years, and 75+ years 2003-2013
- Exhibit 3: Number of new cases of diagnosed diabetes in people aged 20 years or older, by age group—United States, 2002
- Exhibit 4: Total prevalence of diabetes in people aged 20 years or older, by age group—United States, 2002
- Exhibit 5: Total Available U.S. Market Potential for Modified Delivery Insulin 2001-2010
- Exhibit 6: Estimated Market for Insulin by Country (Top 7 World Markets) 2004-2008
- Exhibit 7: Estimated World Market for Inhaled Insulin by Region 2004-2008
- Exhibit 8: Status of Selected Inhaled Insulin Products in Development